Printer Friendly

ROBERTS PHARMACEUTICALS NOTIFIED OF AMATINE APPROVABILITY IN NEW ZEALAND

ROBERTS PHARMACEUTICALS NOTIFIED OF AMATINE APPROVABILITY IN NEW ZEALAND
 EATONTOWN, N.J., Dec. 20 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that the New Zealand regulatory authorities have advised the company of the approvability of Amatine(R) (midodrine) for orthostatic hypotension (low blood pressure). The Health Registration authorities have requested that Roberts supply certain additional data which is readily available and will be provided in the next few weeks. Roberts anticipates final approval and launch in the New Zealand market in the near future. Marketing, sales and distribution activities will be accomplished through a marketing and promotion agreement with a leading New Zealand pharmaceutical firm.
 Amatine is a new drug belonging to the class known as alpha receptor agonists and is sold in Europe and Japan for the treatment of both orthostatic hypotension and stress urinary incontinence. Orthostatic hypotension is a condition involving the sudden drop in blood pressure upon assuming an upright posture resulting in dizziness, weakness or unconsciousness. Patients afflicted with this illness are frequently incapacitated and they often cannot stand upright.
 Robert A. Vukovich, chairman and CEO of Roberts, said, "The approvable status of Amatine in New Zealand further demonstrates Roberts' drug development capabilities as this will be the third country in which Roberts has obtained approval for Amatine. Roberts has previously submitted and received approval for Amatine in Canada and Ireland and we have submitted an NDA for approval of Amatine in the U.S."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 12/20/91
 /CONTACT: Anthony P. Maris of Roberts, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:


GK-OS -- NY051 -- 2680 12/20/91 13:36 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:330
Previous Article:PRIME BANCORP DECLARES 22 PERCENT INCREASE IN QUARTERLY DIVIDEND
Next Article:THE PENN CENTRAL CORPORATION ANNOUNCES INCREASED QUARTERLY DIVIDEND
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES THIRD QUARTER RESULTS
ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS
ROBERTS PHARMACEUTICAL CARDIOVASCULAR DRUG CLINICAL RESULTS TO BE REPORTED AT AMERICAN COLLEGE OF CARDIOLOGY MEETING
ROBERTS PHARMACEUTICAL ANNOUNCES SECOND QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES AGREEMENT TO ACQUIRE MULTI-PRODUCT DRUG LINE FROM GLAXO CANADA
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES 1994 CORPORATE AWARD FOR ORPHAN DRUG DEVELOPMENT
ROBERTS PHARMACEUTICAL CORPORATION REPORTS SIXTH STRAIGHT QUARTER OF PROFITABLE EARNINGS
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES REGULATORY APPROVAL TO SELL PRO-AMATINE UNDER TREATMENT USE AND SALE REGULATIONS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES ITS AGRELIN NEW DRUG APPLICATION HAS BEEN ACCEPTED FOR FILING BY FDA
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN APPROVAL FOR THE CARDIOVASCULAR DRUG EMINASE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters